Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA based assays to predict benefit from immunotherapy in lung cancer require prospective validation.

Keyphrases

endothelial cells
poor prognosis
induced pluripotent stem cells
high throughput
genome wide
pluripotent stem cells
peripheral blood
risk factors
long non coding rna